Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilenya Patent Upheld, But Who's The Biggest Winner – Novartis or Celgene?

Executive Summary

A composition of matter patent for the Novartis MS drug Gilenya expires in 2019, but a recent inter partes review decision upheld a dosing patent that doesn't expire until 2027. However, analysts also touted the victory as a big win for Celgene and its competing S1P modulator ozanimod.

Advertisement

Related Content

Attention Turns To Celgene's Other Pipeline Prospects Following Second Positive Luspatercept Read-Out
Celgene Notches A Needed Win As Acceleron-Partnered Luspatercept Succeeds In MDS
Celgene Shares Good News On Ozanimod, Quietly Dumps Pricey GED-0301
Celgene's Terrie Curran On Building, Broadening The I&I Franchise
Novartis’s Chief Medical Officer On All Things MS And The Science Of Operations
More Bad News: Celgene Reveals Refuse-To-File Letter For Ozanimod In MS
Celgene's Positive Ozanimod Data Puts Focus On MS Commercialization
Safety Is Key As Celgene's Ozanimod Succeeds In First Pivotal MS Test
MS Drug Prices Far Exceed Value Thresholds, Even At Current Discounts – ICER Report
Novartis Sees Real Value Of Ofatumumab In MS, Pays GSK Up To $1Bn

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123407

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel